ZIM Laboratories announced the constitution of an Advisory Board on March 17, 2026, through a circular resolution passed by its Board of Directors. The pharmaceutical company established this advisory body to provide independent advice and strategic guidance on business development and related matters to the management and board.

Advisory Board Composition and Leadership

The newly formed Advisory Board consists of three distinguished industry professionals with extensive experience in healthcare, pharmaceuticals, and financial services:

Strategic Scope and Responsibilities

The Advisory Board will focus on several key areas to support ZIM Laboratories' growth objectives:

• Strategic Planning: Offering advice on long-term vision, mission, and growth strategy
• Business Development: Providing inputs on market expansion, new business lines, and brand strategy
• Industry Insights: Guidance on industry trends, competition analysis, and best practices
• Organizational Excellence: Advising on organizational structure and talent acquisition
• Governance: Supporting risk management and regulatory compliance initiatives

Leadership Profiles

Chairman - Mr. Annaswamy Vaidheesh

Mr. Vaidheesh brings nearly four decades of healthcare and MedTech leadership experience across Asia-Pacific and India. He currently serves as Chairman of Integris Medtech and Non-Executive Chairman of Appasamy Associates. His previous roles include Executive Chairman of Suven Pharmaceuticals, Managing Director of GSK Pharmaceuticals Ltd, and nearly three decades with Johnson & Johnson in various senior leadership positions across Asia-Pacific.

Member - Mr. Gautam Saigal

With over 35 years in financial services, Mr. Saigal has extensive experience in private equity investments, investment banking, and advisory services. He previously served as Managing Director of AA Indian Development Capital Advisors Private Limited and Associate Director of India Liaison Office of American International Group. He currently serves as Managing Partner of Pachira Financial Services LLP and holds board positions across multiple companies.

Member - Mr. Girdhar Balwani

Mr. Balwani is a seasoned pharmaceutical professional with over 40 years of experience across the Asia-Pacific region. His leadership experience includes serving as Managing Director of UCB Pharma (India) for seven years, Regional Director Asia Pacific with UCB Pharma for 10 years, and Managing Director of Menarini for five years. He has demonstrated expertise in sales, marketing, business development, and operations management.

Advisory Framework

The Advisory Board will operate purely in an advisory capacity to the Board of Directors, with no legal, fiduciary responsibilities, statutory authority, execution powers, or control over the company or its management. This structure allows the board to provide strategic guidance while maintaining clear governance boundaries.

About ZIM Laboratories

ZIM Laboratories Limited is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The company maintains state-of-the-art in-house R&D capabilities and offers innovative drug delivery solutions using proprietary technology platforms to enhance patient convenience and treatment adherence.

ZIM Laboratories Limited has announced a scheduled virtual investor meeting with Everflow Partners, demonstrating the company's commitment to maintaining transparent communication with its stakeholders. The pharmaceutical company disclosed this information to stock exchanges on March 16, 2026, ensuring compliance with regulatory requirements.

Meeting Details and Format

The investor engagement is scheduled as a virtual one-to-one session, reflecting the modern approach to stakeholder communication in the pharmaceutical sector. The company has structured this interaction to facilitate direct dialogue between management and the investment partner.

Regulatory Compliance Framework

ZIM Laboratories Limited has ensured full compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically under Regulation 30. The company has proactively informed both BSE Limited and National Stock Exchange of India Limited about the scheduled interaction, maintaining transparency in its investor relations activities.

The pharmaceutical company has explicitly stated that no unpublished price sensitive information will be shared during the meeting, adhering to strict regulatory guidelines that govern such interactions. This commitment underscores the company's dedication to maintaining fair disclosure practices and protecting all stakeholders' interests.

Operational Flexibility

The company has indicated that the meeting schedule remains subject to change due to any exigencies that may arise. This flexibility clause ensures that both parties can accommodate any unforeseen circumstances while maintaining the commitment to stakeholder engagement. The disclosure was signed by Piyush Nikhade, Company Secretary and Compliance Officer, emphasizing the formal nature of this communication and the company's adherence to corporate governance standards.